Type your paragraph here.

    Transforming the Paradigm of Cancer Treatment

GlyTR Therapeutics ‘Cancer Moonshot’ Technology Receives Second Grant from the National Cancer Institute

October 22, 2018 04:10 PM Eastern Daylight Time

IRVINE, Calif.--(BUSINESS WIRE)--GlyTR Therapeutics, Inc. is pleased to announce it has been awarded an approximately $300,000 grant from The National Cancer Institute (NCI), National Institute of Health (NIH) thru the Small Business Technology Transfer Program. This grant award comes on the heels of a $3.4 million grant on its Glycan dependent T cell Recruiter (GlyTR – pronounced ‘glitter’) technology received in September from the Beau Biden Cancer Moonshot initiative at NCI. The new funding will support the company’s development of highly novel cancer immunotherapies that trigger the body’s own immune system to kill cancer.

Cancer Immunotherapy is an area of intense development and investment. However, expansion of targeted immunotherapies such as bi-specific proteins and engineered Chimeric Antigen Receptor (CAR) T cells to the majority of common cancer types is greatly limited by a lack of protein antigens that can be safely targeted. In addition, different therapeutics are required for different cancers, greatly increasing time and cost of development. GlyTR technology addresses both of these issue by targeting ‘Tumor Associated Carbohydrate Antigens’, the most abundant and widely expressed cell surface cancer antigens known to have limited or no expression in normal tissue.

“The funding of these two grants provides scientific validation of GlyTR technology and its potential to greatly broaden cancer immunotherapy to the vast majority common cancers,” says Bob Genthert, an EvoNexus mentor-in-residence and GlyTR Therapeutics’ board member and investor. “This is testament to the herculean efforts that Professor Michael Demetriou MD, Ph.D. and post-doctoral fellow, Raymond Zhou, Ph.D. have put into the discovery of GlyTR technology at the University of California, Irvine.”

To complement the new funding, GlyTR Therapeutics is seeking investors to participate in a Series A financing round to fund the regulatory and commercialization process. The company is also seeking a CEO with proven cancer immunotherapy drug development experience.

GlyTR Therapeutics is based on research derived from UC Irvine’s Research Labs. Professor Michael Demetriou and co-inventor Dr. Raymond Zhou are the inventors and founders of GlyTR Therapeutics. UC Irvine has strongly supported the development of GlyTR through pilot awards from the UC Irvine Center for Applied Innovation and the UCI Anti-Cancer Challenge Research Fund. Dr Zhou has been supported by a fellowship from the UCI Institute for Clinical and Translational Science. GlyTR Therapeutics has been working out of EvoNexus, a non-profit incubator located adjacent to the UC Irvine campus.

About GlyTR

Based in Irvine, Calif., GlyTR Therapeutics is developing a novel immunotherapy platform technology that uniquely targets highly diverse cancer types, ranging from breast cancer to leukemia. GlyTR technology can overcome many of the shortcomings of current immunotherapies by binding to never-before targeted tumors associated carbohydrate antigens (targets) that are common to many cancer types.

For scientific information, contact: mike.demetriou@glytrtherapeutics.com and for investor information and/or the CEO opportunity, contact: bob.genthert@glytrtherapeutics.com.


GlyTR Therapeutics, Inc.
Bob Genthert, (949) 632-2234

UCI awarded $3.4M NIH “Cancer Moonshot” grant to study potential breakthrough in cancer immunotherapy

Novel GlyTR technology may markedly broaden the types of cancers sensitive to immunotherapy

Irvine, Calif. – September 27, 2018 – UCI School of Medicine researchers have been awarded a $3.4 million grant by the National Cancer Institute (NCI) as part of the Beau Biden Cancer Moonshot initiative. The funding will support efforts to provide proof of principal data for an entirely new class of cancer killing immunotherapeutics with the potential to treat highly diverse types of cancer, from leukemia to breast cancer.

Principal investigator, Michael Demetriou, MD, PhD, a professor of neurology, microbiology and molecular genetics and member of the NCI-designated Chao Comprehensive Cancer Center at UCI, will lead the study entitled, “N-glycosylation and immunotherapy for cancer.”

“This grant epitomizes the kind of bench-to-bedside translational cancer research that is emerging from our NCI-designated cancer center,” said Richard Van Etten, MD, PhD, director of the UCI Chao Family Comprehensive Cancer Center. “Dr. Demetriou’s work, supported in part by a seed grant from the UCI Anti-Cancer Challenge event, has the potential to change our current paradigm of cancer immunotherapy by defining a class of new cancer-specific antigens that are broadly applicable to many tumors. We look forward to shepherding this class of therapeutic agents towards a clinical trial in patients.”

For decades, the treatment of cancer has relied on surgical resection, chemotherapy and/or radiotherapy, and new immune-based therapies offer promising new options for cancer treatment. The most potent of these – bi-specific antibodies that cross-link T cells to cancer cells and T cells engineered to express antigen receptors specific to cancer cells (CAR T cells) – induce T cell mediated killing of cancer cells and display extraordinary complete response rates up to ~90% for B cell cancers. However, broadly applying these types of cancer treatments is greatly limited by a lack of protein antigens that can be safely targeted without toxicity.  In addition, different versions of these treatments need to be made for each different cancer type, greatly increasing time and cost of development.

Demetriou and his post-doctoral fellow, Raymond Zhou, PhD, have worked to overcome these barriers by inventing a novel technology called Glycan dependent T cell Recruiter (GlyTR – pronounced ‘glitter’) using pilot funding from the UCI Center for Applied Innovation, the UCI Institute for Clinical and Translational Science and the UCI Anti-Cancer Challenge Research Fund.

Almost all proteins on the surface of cells have complex sugars attached to them.  Abnormal expression of these complex sugars, or ‘glycans’, is nearly a universal feature of cancer and provides the most abundant and widely expressed cell surface cancer antigens known while also having limited or no expression in normal tissue. The generation of potent antibodies specific to these abnormal cancer glycans has proven to be challenging, greatly limiting their usefulness as targets for cancer immunotherapy.

“GlyTR is a disruptive immunotherapy platform technology that can markedly broaden the types of cancers sensitive to immunotherapy by effectively targeting abnormal glycans,” said Demetriou. “We are very excited that the Biden Cancer Moonshot program and the NCI have recognized the great potential of GlyTR technology in the fight against cancer.”

Now funded through the Moonshot Initiative, the UCI team will proceed with characterizing GlyTR technology targeting N-glycans, and examine the efficacy and safety using mouse models. To translate the GlyTR technology to humans, Demetriou and Zhou co-founded a company called GlyTR Therapeutics in 2016 to accelerate the application of GlyTR immunotherapy to treat cancer in humans. The company is supported by UCI Applied Innovation and is incubating at EvoNexus in Irvine, CA.

As a grant recipient, the UCI research team becomes part of the NCI’s Immuno-Oncology Translation Network, which was established to foster collaborative team science approaches to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. As members of the Immuno-Oncology Translation Network (IOTN), the UCI research team will meet regularly with the other awardees to advance immunotherapies for cancer.

The Cancer Moonshot initiative was established to accelerate cancer research and aims to make more therapies available to more patients, while also improving our ability to prevent cancer and detect it at an early stage.

About the UCI School of Medicine

Each year, the UCI School of Medicine educates more than 400 medical students, as well as 200 doctoral and master's students. More than 600 residents and fellows are trained at UC Irvine Medical Center and affiliated institutions. The UCI School of Medicine offers an MD degree, a dual MD/PhD medical scientist training program, PhDs and master’s degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA program, a combined MD/Master's in Public Health or a dual MD/master’s program called the Program in Medical Education for the Latino Community (PRIME-LC). UCI School of Medicine is accredited by Liaison Committee on Medical Accreditation (LCME), and ranks among the top 50 nationwide for research. For more information, visit: som.uci.edu.

About the University of California, Irvine

Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 30,000 students and offers 192 degree programs.  Located in one of the world’s safest and most economically vibrant communities, UCI is Orange County’s second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit www.uci.edu.